€61 Million Cell Therapy Center Opens in Vilnius — Another Step in the “Bio City” Vision
On September 3, 2026, a new €61 million cell therapy and personalized medicine center officially opened at the Vilnius Innovation Industrial Park — part of the third phase of the “Bio City” development, “Bio City III.”
The 3,500 sq. m. facility will develop and manufacture cell therapy products, personalized therapeutic vaccines, regenerative medicine products, and 3D-printed human tissues. The new center is expected to create around 100 highly qualified jobs.
The opening ceremony was attended by the President of the Republic of Lithuania, Gitanas Nausėda, who emphasized the project’s importance for the country’s future: “This is Lithuania’s path to the future… the 21st and 22nd centuries will belong to technologically innovative sectors.”
Prof. Vladas Algirdas Bumelis, founder of the Northway Group, presented the center’s potential in the fight against oncological diseases, explaining how modified lymphocytes can recognize and destroy cancer cells.
LithuaniaBIO was represented at the event by the association’s President, Tomas Andriejauskas.
“Bio City III” is the third phase of the large-scale biotechnology city being developed in Vilnius, encompassing cell, tissue, and organ engineering as well as large-scale microbial manufacturing. The overall “Bio City” project envisions up to €7 billion in investment over the coming decade, around 2,400 jobs, and a goal of increasing the life sciences sector’s contribution to Lithuania’s GDP from 2% to 5% by 2030.
